M
M. Angelyn Bethel
Researcher at University of Oxford
Publications - 28
Citations - 4987
M. Angelyn Bethel is an academic researcher from University of Oxford. The author has contributed to research in topics: Sitagliptin & Diabetes mellitus. The author has an hindex of 18, co-authored 28 publications receiving 4088 citations.
Papers
More filters
Journal ArticleDOI
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
Jennifer B. Green,M. Angelyn Bethel,Paul W. Armstrong,John B. Buse,Samuel S. Engel,Jyotsna Garg,Robert G. Josse,Keith D. Kaufman,Joerg Koglin,Scott Korn,John M. Lachin,Darren K. McGuire,Michael J. Pencina,Eberhard Standl,Peter P. Stein,Shailaja Suryawanshi,Frans Van de Werf,Eric D. Peterson,Rury R. Holman +18 more
TL;DR: Among patients with type 2 diabetes and established cardiovascular disease, adding sitagliptin to usual care did not appear to increase the risk of major adverse cardiovascular events, hospitalization for heart failure, or other adverse events.
Journal ArticleDOI
Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes.
Rury R. Holman,M. Angelyn Bethel,Robert J. Mentz,Vivian P. Thompson,Yuliya Lokhnygina,John B. Buse,Juliana C.N. Chan,Jasmine Choi,Stephanie M. Gustavson,Nayyar Iqbal,Aldo P. Maggioni,Steven P. Marso,Peter Öhman,Neha J. Pagidipati,Neil Poulter,Ambady Ramachandran,Bernard Zinman,Adrian F. Hernandez +17 more
TL;DR: Among patients with type 2 diabetes with or without previous cardiovascular disease, the incidence of major adverse cardiovascular events did not differ significantly between patients who received exenatide and those who received placebo.
Journal ArticleDOI
Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis.
M. Angelyn Bethel,Rishi A Patel,Peter Merrill,Yuliya Lokhnygina,John B. Buse,Robert J. Mentz,Neha J. Pagidipati,Juliana C.N. Chan,Stephanie M. Gustavson,Nayyar Iqbal,Aldo P. Maggioni,Peter Öhman,Neil Poulter,Ambady Ramachandran,Bernard Zinman,Bernard Zinman,Adrian F. Hernandez,Rury R. Holman +17 more
TL;DR: Overall cardiovascular safety across all GLP-1 receptor agonist cardiovascular outcome trials is shown and drugs in this class can reduce three-point major adverse cardiovascular events, cardiovascular mortality, and all-cause mortality risk, albeit to varying degrees for individual drugs, without significant safety concerns.
Journal ArticleDOI
Association Between Sitagliptin Use and Heart Failure Hospitalization and Related Outcomes in Type 2 Diabetes Mellitus: Secondary Analysis of a Randomized Clinical Trial
Darren K. McGuire,Frans Van de Werf,Paul W. Armstrong,Eberhard Standl,Joerg Koglin,Jennifer B. Green,M. Angelyn Bethel,Jan H. Cornel,Renato D. Lopes,Sigrun Halvorsen,Giuseppe Ambrosio,John B. Buse,Robert G. Josse,John M. Lachin,Michael J. Pencina,Jyotsna Garg,Yuliya Lokhnygina,Rury R. Holman,Eric D. Peterson +18 more
TL;DR: Sitagliptin use does not affect the risk for hHF in T2DM, both overall and among high-risk patient subgroups, andMeta-analyses evaluated DPP4i effects on hHF and on h HF or CV death.
Journal ArticleDOI
Association between change in daily ambulatory activity and cardiovascular events in people with impaired glucose tolerance (NAVIGATOR trial): a cohort analysis
Thomas Yates,Thomas Yates,Steven M. Haffner,Phillip J. Schulte,Laine Thomas,Kim M. Huffman,Connie W. Bales,Connie W. Bales,Robert M. Califf,Rury R. Holman,John J.V. McMurray,M. Angelyn Bethel,Jaakko Tuomilehto,Jaakko Tuomilehto,Melanie J. Davies,Melanie J. Davies,William E. Kraus +16 more
TL;DR: In individuals at high cardiovascular risk with impaired glucose tolerance, both baseline levels of daily ambulanceatory activity and change in ambulatory activity display a graded inverse association with the subsequent risk of a cardiovascular event.